CME/CE

Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Brendon Neuen, MBBS, PhD Recent updates to the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) emphasized the expanded role of IV iron replacement therapy in patients with non–dialysis-dependent CKD. The updated guidance emphasizes proactive iron assessment, earlier identification of iron deficiency phenotypes, and individualized selection of iron replacement strategies to improve long-term patient outcomes. Other updates include reclassification of systemic iron deficiency and iron-restricted anemia, plus screening recommendations for iron deficiency and iron-deficient anemia.

Faculty: Maria Pabon, MD Faculty: Robert J. Mentz, MD, FHFSA, FACC In this brief podcast, Drs. Maria Pabon and Robert Mentz explore the evolving role of mineralocorticoid receptor antagonism in heart failure, with emphasis on patients who appear clinically stable yet remain at elevated biologic risk. They contrast steroidal and nonsteroidal MRAs, highlighting differences in receptor selectivity, cardiac-renal distribution, and downstream anti-fibrotic and anti-inflammatory signaling. Faculty address the principle that symptom stability does not equate to disease stability, offering strategies to identify patients with HFpEF or HFmrEF who may benefit from a risk-based treatment approach.

Faculty: Michael Nassif, MD, MSc This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Ahmad Masri, MD, MS Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Ahmad Masri, MD, MS Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Michael Nassif, MD, MSc Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Michael Nassif, MD, MSc Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Ahmad Masri, MD, MS Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: David Staskin, MD Faculty: Matt T. Rosenberg, MD Faculty: Kennedy Koebbe, MSN, RN This audio-only podcast examines where contemporary approaches fall short when managing overactive bladder (OAB) in patients with complex clinical considerations, including women with persistent symptoms and men with coexisting benign prostatic hyperplasia (BPH). Faculty review clinical considerations supporting earlier use of β₃-adrenergic agonists within team-based care pathways. Through case-based scenarios, the program highlights practical strategies for patient selection, reassessment, and treatment escalation in both men and women, including men receiving pharmacologic therapy for BPH who continue to experience storage symptoms.

Host: Carole Bitar, MD, FAAD Guest: Matthew P. Giannetti, MD Guest: Benjamin Ungar, MD On-demand webcast featuring expert-informed best practices for diagnosing and managing patients with systemic mastocytosis (SM) as well as the latest data on new and emerging SM therapies.

Host: Anne Marie Singh, MD On-demand webcast on the role of interleukin (IL)-13 in atopic dermatitis pathophysiology and strategies for leveraging IL-13 inhibitors to address disease burden and improve patient outcomes.

Host: Praveen Akuthota, MD Guest: Anisha Dua, MD, MPH Guest: Michael E. Wechsler, MD, MMSc On-demand webcast on the latest advances in diagnosing and managing patients with eosinophilic granulomatosis with polyangiitis (EGPA), including current data on new EGPA therapies and shared decision-making strategies to help patients achieve and maintain remission.

Host: Marc A. Riedl, MD, MS On-demand webcast with expert faculty presentation on addressing the unmet needs and optimizing treatment for hereditary angioedema (HAE), including long-term prophylaxis therapy, for patients with HAE.

Host: Carlos M. de Castro, MD Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by hemolytic anemia and associated with thrombophilia and bone marrow failure. Early and accurate diagnosis and classification of PNH is essential to optimize outcomes. However, the diagnosis of PNH may be delayed or missed for months or even years in practice, and only 25% of newly diagnosed patients receive any PNH-specific treatment. Moreover, up to 20% of patients treated with C5 inhibitors continue to experience clinically significant extravascular hemolysis, leading to residual anemia and its complications. Thus, several new and novel complement inhibitors have been developed and approved. In this activity, Dr. Carlos de Castro reviews the diagnostic criteria for PNH and best practices for the selection of optimal treatment regimens.

Host: Jorge E. Cortes, MD Although the first-generation tyrosine kinase inhibitors (TKIs) revolutionized the treatment of Ph+ CML-CP, the rate of resistance to these agents is high, and many patients require further treatment with second- and third-line therapy. The development of newer drugs with unique mechanisms that can overcome these resistance phenotypes offers new treatment strategies that can maintain response rates. This activity reviews the current treatment options for newly diagnosed disease and the importance of integrating patient preference when planning therapeutic regimens.

Host: Sara M. Tolaney, MD, MPH The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer, with emerging evidence supporting their utility in the early breast cancer (eBC) setting in combination with adjuvant endocrine therapy. In this educational activity, expert faculty review a clinical case series highlighting the application of CDK4/6 inhibitors in HR+/HER2− eBC, including identification of patients at high risk of recurrence/progression, selection of adjuvant therapy based on the latest clinical evidence and patient-specific factors, and management of treatment-related adverse events. Approaches to recognizing and addressing racial/ethnic health disparities among minority patients will also be discussed, empowering clinicians to make informed decisions that align with achieving health equity.

Guest: Michael J. Mauro, MD Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cells. The hallmark of chronic myeloid leukemia (CML) is an acquired reciprocal translocation between the long arms of chromosomes 9 and 22. This translocation results in the BCR-ABL1 fusion protein, with constitutively active tyrosine kinase activity, and is the underlying driver of CML. BCR-ABL1 testing is widely used to confirm the clinical diagnosis of CML and to assess response to TKI therapy. The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of CML, dramatically improving patient outcomes. Although most CML patients experience excellent clinical outcomes, some CML patients (20-30%) exhibit an acquired resistance to treatment during the disease course, often requiring second- or third-line therapy. Novel TKIs designed to overcome TKI resistance have shown efficacy in early clinical trials and are offering promise to CML patients who do not respond to any of the multiple therapeutic options currently available. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions and answers provide incredible insight and address <span …

Guest: Joyce O&#x27;Shaughnessy, MD By 2040, the global breast cancer burden is expected to increase by 40%, resulting in more than 3 million new cases and 1 million deaths per year. Approximately 65% of cases among women less than 50 years of age and 75% of cases among women over 50 years of age are classified as HR+/HER2-. Although endocrine therapy is employed as standard-of-care treatment for many patients with HR+/HER2- breast cancer, not all such patients respond to endocrine therapy, and many who do initially respond will relapse. CDK 4/6 inhibitors can help overcome mechanisms of endocrine resistance, decrease tumor cell growth, and act synergistically with anti-estrogens. Clinicians are faced with constant change in the breast cancer treatment landscape. Disease heterogeneity, drug resistance, and incorporation of genetic testing into the treatment formula for HR+/HER2- breast cancer patients are all things they must contend with. Understanding practice guideline recommendations and the evidence behind them will allow clinicians to better integrate CDK 4/6 inhibitors into their clinical practice. This Chairman’s Perspective activity features a highlight summary from a nationally recognized expert with relevant and timely information on HR+/HER2- BC, including the latest trial results and accumulating real-world evidence that demonstrates the efficacy and overall safety …

Host: Mark Socinski, MD Guest: Patrick Forde, M.B.B.Ch. Guest: Karen Reckamp, MS, MD Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutation(s). The molecular characterization of tumors using techniques such as next-generation sequencing (NGS) has expanded the understanding of actionable molecular alterations, and in tandem has accelerated the development of drugs to inhibit alterations with greater specificity, leading to the development of novel target-selected agents in NSCLC. The NCCN Guidelines strongly advise assessment of at least 8 targets for NSCLC by NGS, including MET exon 14–skipping mutations (METex14). The FDA has approved two MET inhibitors, capmatinib and tepotinib, for patients with METex14 metastatic NSCLC, and there is ongoing research for other targeted agents. Studies have established that treatment with MET-targeted therapies improves outcomes in patients with METex14, as opposed to patients receiving chemotherapy and/or immunotherapy, which generate a modest activity response. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. That’s why this activity will …

Host: Ayse Tuba Kendi, MD Guest: A. Oliver Sartor, MD Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT). In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.

Host: William Mencia, MD, FACEHP, CHCP Guest: Julie Blatt, MD Guest: Taizo Nakano, MD PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease. The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies. Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.